4:12 PM
 | 
Jun 11, 2018
 |  BC Extra  |  Preclinical News

Summit identifies two new classes of antibiotics

Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT) identified two new types of narrow-spectrum antibiotics targeting new Neisseria gonorrhoeae targets that could help treat gonorrhea.

Summit presented its findings at the American Society for Microbiology Microbe (ASM Microbe) conference in Atlanta.

The incidence of N. gonorrhoeae resistance to existing antibiotics is increasing, suggesting a need for new classes of antibacterial therapies.

Using its...

Read the full 278 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >